To explore potential biomarkers and therapeutic targets, we conducted a transcriptome analysis and identified CCDC50, a poorly investigated gene that is dysregulated in DLBCL (Fig. 1). The gene discussed is CCDC50; the disease is diffuse large B-cell lymphoma.